Novasep

Axplora Aims to Make Pharmaceutical Supply Chains More Stable

Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.

Novasep‐PharmaZell Invests €7.3 Million in APIs

Financed in part by the French government’s France Relance plan, Novasep‐PharmaZell is investing €7.3 million in production of active pharmaceuticals (APIs) at its Mourenx, France, site.

Novasep and PharmaZell Conclude Merger

Following exclusive negotiations that started last September, German API specialist PharmaZell and French CDMO Novasep have merged as of Apr. 7. The combined group will have revenues of nearly €500 million and employ more than 2,000 people across 10 production and R&D sites – seven in Europe, two in India and one in the US.

Novasep Invests in API Capabilities

Novasep, a French CDMO, has announced a €6 million investment to increase and modernize manufacturing capabilities at its Chasse-sur-Rhône site to support new generation APIs in areas such as oncology, central nervous system (CNS) and infectious diseases.

Novasep and McSAF in ADC Partnership

French CDMO Novasep is collaborating with compatriot biotech McSAF on the preclinical production of Adcitmer, a next-generation antibody drug conjugate (ADC) for treating neuroendocrine cancers.

Avid Bioservices Expanding Cell and Gene Therapy

Avid Bioservices, a biologics-oriented CDMO based in the US state of California, is building a new plant in Costa Mesa, California, as part of a plan to expand its cell and gene therapy portfolio. The purpose-built facility, to be located five miles from its current base in Tustin, California, will be dedicated to viral vector development and CGMP manufacturing.

Pharmazell and Novasep in Exclusive Merger Talks

German API specialist PharmaZell and French CDMO Novasep are in exclusive talks about a merger that the companies say would create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.

Novasep Modernizes Mourenx Site

French CDMO Novasep has announced plans to upgrade its API manufacturing facility in Mourenx, increasing its flexibility and competitiveness. The company will invest €6.1 million over three years and create seven full-time jobs.

Novasep Expands HPAPI Capabilities at Le Mans

French CDMO Novasep is expanding its manufacturing capabilities for highly potent active pharmaceutical ingredients (HPAPIs) at its Le Mans site. The investment of more than €4 million will also create 30 new jobs at the site. It did not say when the expanded capabilities would be available.

Novasep and Lysogene in Gene Therapy Pact

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

Novasep and GTP Technology in Monoclonal Antibodies Link

Novasep Appoints Two New Members to its Executive Committee

Novasep reports full year 2013 results

Highly Potent API Demand is On the Rise

'A Unique Moment'

Michael Spagnol New Novasep President and CEO

Novasep Appoints Udo Steinhauer as Fine Chemicals Market Director

Green Chemistry and the Chemical Industry

Chemical Industry’s Expectations for the U.S. Business Climate in 2013

Manufacturing of HPAPIs and ADC Toxins for the Drugs of Tomorrow

Novasep Invests €3 Million to Boost its HPAPI Manufacturing Capabilities

A Changing World for CMOs

Fine Chemicals: The Top 10

Novasep, instrAction Expand Alliance to Include Taxane Purification

The Other Side of the Coin

A Reliable Partner

Linked Together